LOGO
LOGO

Will PGN-EDODM1 Deliver Another Win For PepGen In Myotonic Dystrophy Type 1?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
freedomresults 07012026 lt

Myotonic dystrophy type 1 (DM1) is an inherited, progressive disease that mainly affects the muscles, heart, and nervous system. It occurs in about 1 in 8,000 people worldwide, with roughly 40,000 patients in the United States, 75,000 in Europe, and 15,000 in Japan. Mis-splicing of many important genes is said to be the underlying cause of DM1.

People with DM1 endure muscle stiffness (myotonia), muscle weakness, heart and breathing problems, fatigue, digestive issues, early cataracts, and difficulties with thinking or behaviour. In more severe cases, DM1 can shorten life expectancy, mainly because of heart and lung complications. There are no approved drugs for this rare genetic disorder.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Aug 31 – Sep 04, 2026

September 04, 2026 15:08 ET
The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.